Eli Lilly and Company and Delaware-based Incyte continue to report promising results for baricitinib in combination with remdesivir in treating hospitalized patients with coronavirus.
Incyte, which co-developed the version of its Jakafi blood cancer drug, licensed baricitinib to Lilly, after safety issues arose related to its use to treat arthritis. The Food and Drug Administration limits dosages to arthritis patients.
It was found the drug reduced time to recovery and improved clinical outcomes for patients with Covid-19 compared with remdesivir alone. Remdesivir has been used in a group of drugs used to treat President Trump for coronavirus.
This finding was part of data from the Adaptive Covid-19 Treatment trial sponsored by the National Institute of Allergy and Infectious Diseases part of the National Institutes of Health.
Data were presented at a special International Society for Influenza and other Respiratory Virus Diseases Antiviral Group Virtual Conference on ‘Therapeutics for Covid-19.’ The greatest benefits were observed in patients requiring supplemental oxygen.
As previously reported, a trial demonstrated that the overall patient population treated with baricitinib in combination with remdesivir improved the median time to recovery from eight to seven days in comparison to remdesivir.
The odds of improvement in clinical status at Day 15 were 30 percent greater in patients being treated with baricitinib in combination with remdesivir with a decrease in deaths through day 29.
Lilly is continuing conversations with the U.S. Food and Drug Administration (FDA) around the potential for Emergency Use Authorization of baricitinib to treat hospitalized patients with COVID-19. In the U.S. baricitinib has not been approved by the FDA to treat Covid-19.
See the link below to an earlier story.